TABLE 2.
Variations in definition of CRT response across trials.
| Study | Definition of CRT response | Intervention |
|---|---|---|
| Vijayaraman et al., 2022a | CRT non-response was defined as improvement of LVEF <5% and either worsening or unchanged patient functional status | LBBAP |
| Brown et al., 2022 | Non-responders had an improvement in LV ejection fraction (LVEF) by <5%, and incomplete responders had an improvement in LVEF by >5% with final LVEF <40% at least 3 months post-CRT | CRT optimisation |
| Naqvi et al., 2006 | Symptoms of heart failure post-CRT | CRT optimisation |
| Sepši et al., 2013 | Patients who have developed increase in LVEF >5% and those who had improvement of NYHA class during follow up were classified as responders. Patients who have developed drop in LVEF >5% | CRT optimisation |
| and have decreased the NYHA class during the follow up were classified as non-responders. All between were classified as unchanged | ||
| Saba et al., 2022 | Non-response defined as unchanged or worsened clinical composite score at 6 months post-CRT. | Multi-site pacing |
| Leclercq et al., 2019 | Response defined as <15% reduction in left ventricular end-systolic volume (LVESV) at 6 months post-CRT. | Multisite pacing |
| Bordachar et al., 2018 | Non-response defined as unchanged or worsened clinical composite score 6 months post-CRT. | Multisite pacing |
| van Gelder et al., 2016 | Non-response defined as remaining NYHA class 3 or 4 at least 6 months post-CRT. | Endocardial pacing |
| Sidhu et al., 2020 | Non-response defines as unchanged or worsening of symptoms or New York Heart Failure (NYHA) functional class after at least 6 months post-CRT. | Leadless endocardial pacing |
| Chun et al., 2020 | Decrease in (LV) end-systolic volume > 15% on echocardiography 6 months after implantation | Sacubitril-Valsartan |
| Giaimo et al., 2018 | Non-response defined as previously treated with CRT for at least 6 months and remained classified as New York Heart Association (NYHA) functional class III or IV despite optimal medical therapy; the echocardiographic assessment showed lack of decrease of the left ventricular end-systolic volume (LVESV) of at least 10% and residual moderate-to-severe or severe FMR. | Mitraclip |